SCHEMBL19472176

SCHEMBL19472176

O=c1oc2ccccc2c2ccc(-c3ccc4c(c3)c3ccccc3c(=O)n4-c3ccc4c(c3)c(=O)oc3ccccc34)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.43
▸ RXFP1 Q9HBX9 2/20 0.43
▸ PDE2A O00408 1/20 0.38
▸ KDM4E B2RXH2 4/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ MAPK1 P28482 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ CA9 Q16790 2/20 0.36
▸ PLA2G2A P14555 2/20 0.36
▸ PLA2G4A P47712 2/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19472173 0.96 PLA2G2A (0.41) NPSR1RXFP1PDE2AKDM4EL3MBTL1
SCHEMBL19472128 0.94 NPSR1 (0.42) NPSR1RXFP1PDE2AKDM4EL3MBTL1
SCHEMBL17637779 0.93 ALDH1A1 (0.41) NPSR1RXFP1PDE2AKDM4EL3MBTL1
SCHEMBL17637780 0.93 NPSR1 (0.42) NPSR1RXFP1KDM4EL3MBTL1MAPT
SCHEMBL19472174 0.93 MAPK1 (0.46) NPSR1RXFP1PDE2AKDM4EL3MBTL1
SCHEMBL19472139 0.91 NPSR1 (0.40) NPSR1RXFP1PDE2AKDM4EL3MBTL1
SCHEMBL17637842 0.91 NPSR1 (0.43) NPSR1RXFP1PDE2AKDM4EL3MBTL1
SCHEMBL14933570 0.90 PLA2G2A (0.40) NPSR1RXFP1KDM4EMAPTALDH1A1
SCHEMBL21636017 0.89 MAOA (0.40) NPSR1RXFP1KDM4EMAPTALDH1A1
SCHEMBL14933531 0.89 PLA2G2A (0.39) KDM4EMAPTALDH1A1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197887-B1 HETEROCYCLIC COMPOUNDS WITH BENZO[C]COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2020-09-23 — — EP disclosed
US-10377766-B2 Heterocyclic compounds with benzo(c)coumarin-structures MERCK PATENT GMBH (DE) 2019-08-13 — — US disclosed
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2017-10-19 — — US disclosed
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2017-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES NISCH, SIRT3, NQO1 NPSR1 2494/4885RXFP1 4685/4885PDE2A 3634/4885
US-10377766-B2 Heterocyclic compounds with benzo(c)coumarin-structures NISCH, SIRT3, NQO1 NPSR1 2494/4885RXFP1 4685/4885PDE2A 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback